Press "Enter" to skip to content

Posts tagged as “Prednisone”

Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy – MD Linx

admin 0

Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy  MD…

Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience. – UroToday

admin 0

Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience.  UroToday “prostate cancer” – Google News

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial – The Lancet

admin 0

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial  The Lancet “prostate cancer” – Google News

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. – UroToday

admin 0

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.  UroToday Docetaxel prednisone is a standard of care for men with metastatic castration-resistant prostate cancer (mCRPC),…

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT). – UroToday

admin 0

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).  UroToday The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant…

ASCO 2019: Abiraterone Acetate plus Prednisone without Continuing LHRH-Therapy in Patients with Metastatic Chemotherapy: Naive Castrations-Resistant Prostate Cancer — Results from the SPARE-Trial – UroToday

admin 0

ASCO 2019: Abiraterone Acetate plus Prednisone without Continuing LHRH-Therapy in Patients with Metastatic Chemotherapy: Naive Castrations-Resistant Prostate Cancer — Results from the SPARE-Trial  UroToday Chicago, IL (UroToday.com) Cougar 301 and Cougar…

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. – UroToday

admin 0

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.  UroToday The negative results are consistent with the negative results…

ASCO 2019: Pembrolizumab plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients with Metastatic Castrate Resistant Prostate Cancer: Cohort B of the Phase 1b/2 KEYNOTE-365 study – Medical Oncologist Perspective – UroToday

admin 0

ASCO 2019: Pembrolizumab plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients with Metastatic Castrate Resistant Prostate Cancer: Cohort B of the Phase 1b/2 KEYNOTE-365 study – Medical Oncologist Perspective  UroToday…